Drug Trial Radar · NCT07834346
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
252
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Oct 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Hellenic Institute for the Study of SepsisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with community-acquired pneumonia (CAP), sepsis, and sepsis-induced immunoparalysis (SII). The primary objective is to evaluate the effect of clarithromycin on the incidence of new infection, including worsening or recurrence of the initial CAP episode, new infections at other sites, and secondary sepsis during the 28-day follow-up period. Secondary objectives are to investigate the impact of clarithromycin on mortality, sepsis response, type of secondary infection, time to antimicrobial escalation, hospital readmission, quality of life, cost-effectiveness, and biomarkers of sepsis-induced immunoparalysis. Researchers will compare clarithromycin plus standard-of-care antibiotic therapy to placebo plus standard-of-care antibiotic therapy. Participants will: * Receive clarithromycin or placebo, administered orally or intravenously, in addition to standard-of-care antibiotic therapy for up to 7 days. * Be evaluated during treatment and follow-up through Day 28, with additional assessment of mortality, hospital readmission, and health status through Day 90.
Conditions
- Sepsis
Interventions
PlaceboDrug
There is no other intervention in this clinical study and participation in another clinical study is an exclusion criterion.
clarithromycinDrug
There is no other intervention in this clinical study and participation in another clinical study is an exclusion criterion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of new infectionTime frame: Day 1 through Day 28.
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
General University Hospital of Patras, Department of Internal Medicine
Pátrai, Achaea, Greece · Recruiting
Evaggelismos Hospital, 1st Department of Internal Medicine
Athens, Attica, Greece · Recruiting
General Hospital of Athens Korgialenio Benakio H.R.C, Intensive Care Unit
Athens, Attica, Greece · Recruiting
General Hospital of Athens Korgialenio Benakio H.R.C., 1st Department of Internal Medicine
Athens, Attica, Greece · Recruiting
General Hospital of Athens G.Gennimatas, 1st Department of Internal Medicine
Athens, Attica, Greece · Recruiting
Thoracic General Hospital of Athens I Sotiria, 3rd University Department of Internal Medicine
Athens, Attica, Greece · Recruiting
Thoracic General Hospital of Athens I Sotiria, 6th Department of Pulmonary Medicine
Athens, Attica, Greece · Recruiting
General Hospital of Athens Alexandra, Ηigh Dependency Unit of Department of Clinical Therapeutics
Athens, Attica, Greece · Recruiting
University General Hospital Attikon-General Hospital of West Attica H Agia Varvara, 2nd Department of Propaedeutic Medicine
Athens, Attica, Greece · Recruiting
University General Hospital Attikon-General Hospital of West Attica H Agia Varvara, 4th Department of Internal Medicine
Athens, Attica, Greece · Recruiting
General Oncological Hospital of Kifisia Agioi Anargyroi, Intensive Care Unit
Athens, Attica, Greece · Recruiting
University General Hospital of Ioannina, 1st Department of Internal Medicine
Ioannina, Ioannina, Greece · Recruiting
University General Hospital of Thessaloniki Ahepa, Intensive Care Unit
Thessaloniki, Thessaloniki, Greece · Recruiting
Ippokratio General Hospital of Thessaloniki, 2nd Propaedeutic Department of Internal Medicine
Thessaloniki, Thessaloniki, Greece · Recruiting
General Hospital of Thessaloniki Papageorgiou, Department of Internal Medicine
Thessaloniki, Thessaloniki, Greece · Recruiting
Geniko Nosokomeio Thessalonikis George Papanikolaou, Intensive Care Unit
Thessaloniki, Thessaloniki, Greece · Recruiting
University General Hospital of Alexandroupolis, 2nd Department of Internal Medicine
Alexandroupoli, Thrace, Greece · Recruiting
General Hospital of Eleusina Thriasio, 1st Department of Internal Medicine
Elefsina, West Attica, Greece · Recruiting
General Hospital of Eleusina Thriasio, 2nd Department of Internal Medicine
Elefsina, West Attica, Greece · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.